## International Congress Schedule-at-a-Glance

### Sunday, September 22
- 8:00: Therapeutic Plenary Session 8:00 - 10:00
- 10:00: MDS Regional Assemblies 10:00 - 11:00

### Monday, September 23
- 8:00: Plenary Session (Presidential Lectures) 8:00 - 10:00
- 9:30: Break
- 10:00: MDS Business Meeting 9:30 - 10:30
- 11:00: Therapeutic Plenary Session 11:00 - 13:00

### Tuesday, September 24
- 8:00: Plenary Session 8:00 - 9:30
- 10:30: Break 10:30 - 10:45
- 11:00: Corporate Therapeutic Symposia 12:45 - 13:45
- 12:00: Poster Sessions & Guided Poster Tours 13:45 - 15:15

### Wednesday, September 25
- 8:00: Plenary Session 8:00 - 9:30
- 10:00: Plenary Session (Controversies) 10:00 - 12:00
- 11:00: Plenary Session (Grand Rounds) 10:30 - 12:30

### Thursday, September 26
- 8:00: Plenary Session 8:00 - 9:30
- 10:00: Plenary Session (Hot Topics) 10:00 - 11:00
- 11:00: Plenary Session 10:00 - 12:00

### Legend:
- **CME Accredited Sessions**
- **Non-CME Educational Activities**
- **Corporate Therapeutic Symposia (non-CME)**
- **MDS Activities**
- **Events**
- **Breaks**

### Themed sessions

### Recorded sessions

### Ticketed sessions
# Table of Contents

Welcome to Nice ................................................................. 2
About MDS - Purpose, Mission and Goals ........................................ 2
CME Information .................................................................. 3
Floor Plan ........................................................................... 4
International Congress Session Definitions ............................... 5
Scientific Program ................................................................ 6
  Sunday, September 22, 2019 ............................................. 6
  Monday, September 23, 2019 ............................................. 7
  Tuesday, September 24, 2019 ........................................... 11
  Wednesday, September 25, 2019 ..................................... 16
  Thursday, September 26, 2019 ........................................ 20
  Non-CME Educational Activities ....................................... 21
Corporate Therapeutic Symposia Schedule ............................ 22
Abstract Information .......................................................... 23
Poster Session Schedule ..................................................... 24
Guided Poster Tour Schedule ............................................. 25
MDS Pavilion Schedule ....................................................... 26
International Congress Events ............................................. 27
Faculty Listing ..................................................................... 29
Acknowledgements ............................................................. 32

---

## Download the Free MDS International Congress App

mdscongress.org/app

## Search for MDS Congress

The MDS International Congress app is your complete resource for:
- Abstracts
- Session Evaluations
- Poster Schedules
- Speaker Information

Sponsored by: Zambon
Welcome to Nice

Dear Colleagues,

On behalf of the International Parkinson and Movement Disorder Society (MDS), we are pleased to welcome you to the International Congress of Parkinson’s Disease and Movement Disorders.

Nice is a charming, picturesque city nestled on the southeast coast of France at the foot of the Alps and extending along the Mediterranean Sea.

In addition to the draw of the dynamic landscape, including the Promenade des Anglais situated beside marine reserves and breathtaking ocean views, Nice is recognized for its distinctive architecture and history, with an abundance of historical museums, art galleries, castles, and palaces. The territory is also home to several major research centers and global scientific laboratories, making it the idyllic location for the 2019 International Congress.

We look forward to gathering as a community of clinicians, scientists, and healthcare professionals to learn about the latest advancements and research in the field of Movement Disorders. We expect inspiring discussions, invaluable networking opportunities, and an unforgettable experience.

With kind regards,

Christopher Goetz
President, International Parkinson and Movement Disorder Society, 2017-2019

H.A. Jinnah
Chair, Congress Scientific Program Committee, 2017-2019

Jean-Christophe Corvol
Co-Chair, Congress Scientific Program Committee, 2019

About MDS - Purpose, Mission and Goals

The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control.

Purpose:
The objective and mission of the Society shall be to advance the neurological sciences pertaining to movement disorders; to improve the diagnosis and treatment of patients; to operate exclusively for scientific, scholarly and educational purposes; to encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses, for sharing ideas and for advancing the related clinical and scientific disciplines; to encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists; and to collaborate with other related professional and lay organizations.

Mission and Goals:
To disseminate knowledge about movement disorders by:
• Providing educational programs for clinicians, scientists and the general public designed to advance scientific and clinical knowledge about movement disorders
• Sponsoring International Congresses and symposia on movement disorders
• Collaborating with other international organizations and lay groups
• Publishing journals, videotapes and other collateral materials committed to high scientific standards and peer review

To promote research into causes, prevention and treatment of movement disorders by:
• Using the Society’s influence and resources to enhance support for research
• Facilitating the dissemination of information about research
• Encouraging the training of basic and clinical scientists in Movement Disorders and related disorders

For the purposes of favorably affecting the care of patients with movement disorders, the Society will provide expertise, advice and guidance to:
• Regulatory agencies to assist them in the approval process of safe and effective therapeutic interventions
• The public (media) and patient support groups by informing them of new research and therapeutic advances
• Governments to assist them in the development of policies that affect support of research and patient care
• Educational efforts to assist in developing standards of training in the specialty
CME Information

Target Audience
Clinicians, researchers, post-doctoral fellows, medical residents, medical students, allied health professionals with an interest in current clinical trends and approaches for the diagnosis and treatment of movement disorders.

Objectives
1. Evaluate the pharmacological and non-pharmacological management options available for Parkinson's disease and other movement disorders
2. Discuss the diagnostic approaches and tools available for Parkinson's disease and other movement disorders
3. Describe the pathogenesis and neurobiology of Parkinson's disease and other movement disorders

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement
The International Parkinson and Movement Disorder Society designates this education activity for a maximum of 33.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Satisfactory Completion
Participants must complete an evaluation for each session they attend to receive continuing medical education credit. Your chosen session(s) must be attended in their entirety. Partial credit of individual sessions is not available.

Evaluations
Evaluations are considered part of the course. All evaluations must be completed by Monday, September 30, 2019. Evaluations are available via the MDS International Congress app. Delegates must be logged in to the MDS International Congress app to access evaluations.

Claiming CME
Please visit www.mdscongress.org to claim CME for this activity. Please be advised CME must be claimed by November 26, 2019. Please contact education@movementdisorders.org with any questions.

Faculty Disclosures
All individuals in control of content for the MDS International Congress are required to disclose all relevant financial relationships with commercial interests as defined by the ACCME. Disclosure information is available online at www.mdscongress.org and via the MDS International Congress app.

Content Validity Statement
All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.

EACCME Accreditation Statement
The International Congress of Parkinson's Disease and Movement Disorders, Nice, France, 22/09/2019-26/09/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 32* European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

*The EACCME® awards ECMEC®s on the basis of One hour = 1 ECMEC ®. The EACCME® does not award fractions of credits.
International Congress Session Definitions

CME Accredited Sessions

2019 International Congress Themed Sessions: At each annual International Congress, the Congress Scientific Program Committee (CSPC) selects a theme that is highlighted throughout the meeting. This year’s theme, **Translating the Science of Movement Disorders into Clinical Practice**, will be showcased with international experts serving as faculty. Delegates can elect to attend any or all of these sessions.

**Guided Poster Tours:** This guided tour gives small groups of delegates the opportunity to hear discussion on a select group of abstracts in several different topics.

**Controversies:** This Plenary Session is designed to involve all International Congress delegates. Content is prepared to stimulate interest and debate among a panel of experts. Views from several angles will be addressed as discussion of pre-selected “hot” topics will be open for debate among the panelists.

**Grand Rounds:** In this interactive session, MDS experts will examine both common and rare movement disorder patients. The audience will learn how they formulate diagnoses and manage these interesting and challenging patients.

**Parallel Sessions:** These concurrent sessions provide an in-depth summary of new clinical and basic research findings, state-of-the-art treatment options, and future strategies on a variety of focused topics within the field of Movement Disorders.

**Plenary Sessions:** These sessions provide an overview of the latest clinical and basic science research findings and state-of-the-art information relating to topics of broad interest within the field of Movement Disorders.

**Skills Workshops:** These concurrent sessions provide practical illustrations of clinical or scientific techniques relevant to the field of Movement Disorders through video examples and equipment demonstrations.

**Special Topics in Movement Disorders:** These interactive sessions address “hot” topics in science or medicine using a variety of different formats that may include lectures, video presentations, and audience interaction.

**Teaching Courses:** These educational programs provide up-to-date information focused on a single topic. The sessions highlight both the clinical and basic science of topics of relevance to Movement Disorder specialists. The sessions are unique in providing a syllabus that includes a review of the topic and the presentation slides.

**Therapeutic Plenary Sessions:** These sessions provide an overview of the latest, state-of-the-art treatment options in the diagnosis and management of Parkinson’s disease and other movement disorders.

**Video Sessions:** These concurrent sessions focus on video demonstrations to provide an overview of clinical movement disorders.

MDS Pavilion: The MDS Pavilion is an interactive presentation space designed to provide delegates with valuable information on MDS’ initiatives and programs, insight and MDS expert advice, and various ways to get involved with the Society.

Poster Sessions: Poster sessions give each delegate an opportunity to view their colleagues’ posters on the most current research in the field of Movement Disorders. Posters are available for daily viewing and authors are present for 90 minutes to discuss their work and answer questions.

Science of Industry Sessions: These interactive sessions will provide attendees with a non-CME educational opportunity to learn about novel therapeutic agents under development by industry. Sessions may incorporate faculty working in industry, and topics may address specific research practices in development within the field of Movement Disorders.

International Congress Events

**Health Professionals Networking Meeting:** Join the MDS Health Professionals (Non-Physician) Special Interest Group (SIG) as they discuss exciting updates and current trends in the field. Open to all registered delegates and there is no additional fee to attend.

**MDS Video Challenge:** The goal of this event is for delegates to observe how MDS experts approach unusual and challenging cases as presented by representatives from Movement Disorder Centers around the world.

**Welcome Ceremony:** All registered International Congress delegates are warmly invited to attend the Welcome Ceremony for no additional fee.

**Young Delegates Networking Event:** This event will provide an excellent opportunity for delegates who are in the beginning phase of their career to network and socialize with other up-and-coming experts in the field. This event is open to all registered delegates and there is no additional fee to attend.

MDS Activities

**MDS Business Meeting:** Open to all International Congress delegates, the Society encourages Members to attend the MDS Business Meeting to receive updates from the MDS President and other MDS Officers on the Society, the various Regional Sections, to participate in the Officers’ and International Executive Committee (IEC) election and to discuss other Society activities.

**Regional Assemblies:** Delegates from each of the various MDS Regional Sections (MDS-AOS, MDS-ES, MDS-PAS, and MDS-Africa) are invited to participate in the Regional Assemblies to receive updates on activities within the sections.

International Congress Faculty Roles

**Chair:** Facilitates the learnings of the session; ensures that learning objectives are met during the presentation(s), and engages the learners as needed.

**CSPC Liaison:** Develops the session from the onset and provides guidance to ensure that the overall objective is met.

**Speaker / Presenter:** Creates and delivers the presentation materials, and participates in the dialogue of the session.

Non-CME Educational Activities

**Guided Poster Tours:** Guided Poster Tours give small groups of delegates an opportunity to hear discussion on a select group of abstracts in several different topics.
Sunday, September 22, 2019

1101 Therapeutic Plenary Session

Recognition and Treatment of Early Stage Parkinson’s Disease
8:00 – 10:00
Location: Apollon Auditorium, Level 2, 3
Chairs: Franck Durif, France
Susan Fox, Canada
8:00 Distinguishing Prodromal and Early Parkinson’s Disease
Daniela Berg, Germany
8:40 Treatment of Early Parkinson’s Disease
Shen-Yang Lim, Malaysia
9:20 Disease Modifying Treatment for Parkinson’s Disease: Current and Future
Olivier Rascol, France
CSPC Liaison: Shengdi Chen, People’s Republic of China
At the conclusion of this session, participants should be better able to:
1. Discuss the concept of prodromal Parkinson’s disease and its evolution to Parkinson’s disease
2. Summarize the non-pharmacological and pharmacologic treatment of early stage Parkinson’s disease
3. Review the history and the future of disease modifying treatment for Parkinson’s disease
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

MDS-AOS Regional Assembly
10:00-11:00
Location: Méditerranée 3, Level 1
All delegates from Asia and Oceania are encouraged to attend.

MDS-ES Regional Assembly
10:00–11:00
Location: Méditerranée 1, Level 1
All delegates from Europe are encouraged to attend.

MDS-PAS Regional Assembly
10:00–11:00
Location: Méditerranée 2, Level 1
All delegates from Pan America are encouraged to attend.

MDS-Africa Assembly
10:00–11:00
Location: Gallieni 1 + 2, Level 2
All delegates from the African continent are encouraged to attend.

1102 Therapeutic Plenary Session

Recognition and Treatment of Complications in Later Stage Parkinson’s Disease
11:00 – 13:00
Location: Apollon Auditorium, Level 2, 3
Chairs: Elena Moro, France
Louis Tan, Singapore
11:00 Motor and Non-Motor Fluctuations and Dyskinesias
Angelo Antonini, Italy
11:40 Cognitive, Behavioral and Psychiatric Problems
Jennifer Goldman, USA
12:20 Gait, Balance and Falls
Nir Giladi, Israel
CSPC Liaison: Han-Joon Kim, South Korea
At the conclusion of this session, participants should be better able to:
1. Illustrate the phenomenology and treatment of the motor and non-motor fluctuations and dyskinesias in later stage Parkinson’s disease
2. Review cognitive, behavioral and psychiatric problems and their treatment in later stages of Parkinson’s disease
3. Identify common axial problems affecting gait and balance, and their treatment in later stages of Parkinson’s disease
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

1103 Therapeutic Plenary Session

Diagnosis and Treatment of Atypical Parkinsonian Disorders
14:30 – 16:30
Location: Apollon Auditorium, Level 2, 3
Chairs: Irene Litvan, USA
François Tison, France
14:30 Clinical Manifestations of Atypical Parkinsonian Disorders
Irene Litvan, USA
15:10 Ancillary Investigations for the Diagnosis of Atypical Parkinsonian Disorders
Maria Teresa Pellecchia, Italy
15:50 Therapeutic Options for Atypical Parkinsonian Disorders
Gregor Wenning, Austria
CSPC Liaison: Wassilios Messner, France
At the conclusion of this session, participants should be better able to:
1. Distinguish atypical parkinsonian disorders based on clinical features
2. Discuss ancillary investigations for the diagnosis of atypical parkinsonian disorders
3. Review therapeutic options for atypical parkinsonian disorders
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Sunday, September 22, 2019

1104 Therapeutic Plenary Session

Recognition and Treatment of Dystonia, Tremor and Ataxia
17:00 – 19:00
Location: Apollon Auditorium, Level 2, 3

Chairs: Antonio Strafella, Canada
Christine Tranchant, France

17:00 Therapeutic Options for Dystonia
Marie Vidailhet, France

17:40 Treatment Options for Tremor
Elan Louis, USA

18:20 Management of Ataxia
Elizabeth Slow, Canada

CSPC Liaison: Antonio Strafella, Canada

At the conclusion of this session, participants should be better able to:
1. Identify management strategies for dystonia
2. Select treatment options for tremor
3. Summarize management options for ataxia

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

Welcome Ceremony
19:30-21:30
Location: Apollon Auditorium, Level 2, 3

Monday, September 23, 2019

2101 Plenary Session

Presidential Lectures
8:00 – 10:00
Location: Apollon Auditorium, Level 2, 3

Chairs: Christopher Goetz, USA
Claudia Trenkwalder, Germany

8:00 Stanley Fahn Lecture: Leadership and Mentorship: The Partners of Success
Cynthia Comella, USA

9:00 Junior Award Lectures
Eleonora Fiorenzato, Italy
Juan Li, Canada

9:30 C. David Marsden Lecture: Reduced Penetration of Hereditary Movement Disorders: Elucidating Mechanisms of Endogenous Disease Protection
Christine Klein, Germany

At the conclusion of this session, participants should be better able to:
1. Describe the essential elements of good leadership and mentorship

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

The MDS Paper of the Year and Honorary Member Awards will also be presented at the beginning of this session.

2102 Plenary Session

Update on Neurosurgical Interventions for Movement Disorders
10:30 – 12:30
Location: Apollon Auditorium, Level 2, 3

Chairs: Jean-Philippe Azulay, France
Stéphane Palfi, France

10:30 Redefining Neurosurgical Indications and Interventions for Movement Disorders
Helen Bronte-Stewart, USA

11:10 Lessons Learned and Current Developments in Neuromodulation
Maria Fiorella Contarino, Netherlands

11:50 Overview on MRI-Focused Ultrasound
Clement Hamani, Canada

CSPC Liaison: Elena Moro, France

At the conclusion of this session, participants should be better able to:
1. Identify signs and appropriate surgical intervention for patients with movement disorders
2. Describe pros and cons of different neuromodulation treatments, including DBS
3. Summarize the latest available knowledge about MRI-focused ultrasound

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
### Cognitive Issues in Parkinson’s Disease

**15:30 – 17:30**

**Location:** Apollon Auditorium, Level 2, 3

**Chairs:** Bruno Dubois, *France*
Jennifer Goldman, *USA*

**15:30** Cognitive Impairment: Clinical Phenotype and Heterogeneity  
Caroline Williams-Gray, *United Kingdom*

**16:10** Neuroimaging Markers of Cognitive Dysfunction  
Antonio Strafella, *Canada*

**16:50** Management Strategies for Cognitive Issues  
Irena Rektorova, *Czech Republic*

**CSPC Liaison:** Jennifer Goldman, *USA*

At the conclusion of this session, participants should be better able to:
1. Illustrate the clinical phenotype and heterogeneity associated with cognitive issues in Parkinson’s disease
2. Discuss neuroimaging markers associated with cognitive issues in Parkinson’s disease
3. Review management strategies for cognitive issues in Parkinson’s disease

**Recommended Audience:** Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

---

### Parkinson's Disease and Atypical Parkinsonism: Tauopathies vs. Synucleinopathies

**15:30 – 17:30**

**Location:** Les Muses 1, Level 3

**Chairs:** Irene Litvan, *USA*
Maria Stamatoiu, *Greece*

**15:30** Diagnostic Pearls in Recognizing Tauopathies vs. Synucleinopathies  
Stephen Reich, *USA*

**16:10** Pathophysiology and Targets for Therapeutic Interventions  
Lawrence Golbe, *USA*

**16:50** Disease Modifying Therapies  
Huw Morris, *United Kingdom*

**CSPC Liaison:** Irene Litvan, *USA*

At the conclusion of this session, participants should be better able to:
1. Describe how to distinguish patients with tauopathies from synucleinopathies
2. Summarize the mechanisms leading to the development and spread of tauopathies versus synucleinopathies
3. Describe the biological rationale for experimental therapies

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

---

### Science of Industry Session (non-CME)

See page 21 for complete session information.
Monday, September 23, 2019

2208 Parallel Session

**Translating the Science of Functional (Psychogenic) Movement Disorders into Clinical Practice**

15:30 – 17:30

**Location:** Athéna Auditorium, Level 2

**Chairs:** Beomseok Jeon, South Korea
Kathrin LaFaver, USA

**15:30** Connecting Pathophysiology and Risk Factors to Clinical Care in Functional Movement Disorders
Selma Aybek Rusca, Switzerland

**16:10** Treatment Choices in Functional Movement Disorders: Established and Novel Treatments
Kathrin LaFaver, USA

**16:50** Putting It Together: How to Develop and Run a Clinical Service for Functional Movement Disorders
Mark Edwards, United Kingdom

**CSPC Liaison:** Beomseok Jeon, South Korea

At the conclusion of this session, participants should be better able to:
1. Explain the pathophysiology and risk factors of functional movement disorders
2. Discuss the evidence base for physiotherapy and multidisciplinary rehabilitation in functional movement disorders
3. Discuss how to design care pathways and run a service for people with functional movement disorders

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

*This course will be recorded and developed into an online MDS eLearning module that will be available to MDS Members.*

2309 Teaching Course

**Integrated Management of Movement Disorders: The Example of Parkinson's Disease**

15:30 – 17:30

**Location:** Méditerranée 1, Level 1

**Chairs:** Alice Nieuwboer, Belgium
Mayela Rodriguez Violante, Mexico

**15:30** How to Organize Multidisciplinary Care
Carsten Eggers, Germany

**16:10** Physical and Occupational and Speech Therapy
Alice Nieuwboer, Belgium

**16:50** Shifting Management Towards Patient-Centered Care and Empowerment
Maria Piemonte, Brazil

**CSPC Liaison:** Wassilios Meissner, France

At the conclusion of this session, participants should be better able to:
1. Describe the organization of a multidisciplinary care team for Parkinson’s disease and other movement disorders
2. Apply the evidence for physical, occupational and speech therapy for Parkinson’s disease
3. Discuss how to design care pathways and run a service for people with functional movement disorders

**Recommended Audience:** Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

*This course will be recorded and developed into an online MDS eLearning module that will be available to MDS Members.*

2310 Teaching Course

**Using Imaging Methods for Movement Disorders**

15:30 – 17:30

**Location:** Méditerranée 2, Level 1

**Chairs:** Han-Joon Kim, South Korea
Stephane Lehericy, France

**15:30** Structural and Functional MRI Imaging
Stephane Lehericy, France

**16:10** Brain Imaging Using PET and SPECT
Jee-Young Lee, South Korea

**16:50** Other Novel and Non-CNS Imaging Techniques
Thilo Van Eimeren, Germany

**CSPC Liaison:** Han-Joon Kim, South Korea

At the conclusion of this session, participants should be better able to:
1. Explain the role of MRI techniques in the diagnosis of Parkinson’s disease and other movement disorders
2. Discuss how PET and SPECT imaging can detect brain alterations in Parkinson’s disease and other movement disorders
3. Report the use and limitations of other neuroimaging techniques in Parkinson’s disease and other movement disorders (TCS, NIRS, OCT, and MIBG)

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

*This course will be recorded and developed into an online MDS eLearning module that will be available to MDS Members.*

2411 Skills Workshop

**Advanced Therapies for Movement Disorders: Difficult Cases and Pitfalls**

18:00 – 19:30

**Location:** Les Muses 1, Level 3

**Chairs:** Tove Henriksen, Denmark
Andrea Kühn, Germany

**CSPC Liaisons:** Elena Moro, France
Claudia Trenkwalder, Germany

In this interactive session, the presenters will describe the selection process of parkinsonian patients who can benefit from advanced therapies, and how to recognize and manage issues and complications related to these treatments. In particular, cases presenting with infusion therapies such as apomorphine pump and levodopa intestinal infusion, and Deep Brain Stimulation therapy will be discussed.

At the conclusion of this session, participants should be better able to:
1. Describe the selection of patients for the different advanced therapies
2. Recognize and manage problems and side effects during infusion therapies with apomorphine and LDCD
3. Identify and manage the most frequent problems related to neuromodulation surgery and post-surgery management

**Recommended Audience:** Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

*This course will be recorded and developed into an online MDS eLearning module that will be available to MDS Members.*
### Monday, September 23, 2019

<table>
<thead>
<tr>
<th>Session</th>
<th>Description</th>
<th>Time</th>
<th>Location</th>
<th>CSPC Liaison</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2412</strong> Skills Workshop</td>
<td>Using Genetic Tools for Diagnosis</td>
<td>18:00 – 19:30</td>
<td>Les Muses 3, Level 3</td>
<td>Maria Stamelou, Greece</td>
</tr>
<tr>
<td><strong>2413</strong> Skills Workshop</td>
<td>Metabolic Movement Disorders</td>
<td>18:00 – 19:30</td>
<td>Méditerranée 2, Level 1</td>
<td>Maria Stamelou, Greece</td>
</tr>
<tr>
<td><strong>2414</strong> Video Session, cont.</td>
<td>Atypical Parkinsonism</td>
<td>18:00 – 19:30</td>
<td>Athéna Auditorium, Level 2</td>
<td>Ryosuke Takahashi, Japan</td>
</tr>
<tr>
<td><strong>2514</strong> Video Session</td>
<td>Atypical Parkinsonism</td>
<td>18:00 – 19:30</td>
<td>Hermès Auditorium, Level 2</td>
<td>Esther Cubo Delgado, Spain</td>
</tr>
<tr>
<td><strong>2515</strong> Video Session</td>
<td>A Case-Based Approach to Dystonia: What Would You Do?</td>
<td>18:00 – 19:30</td>
<td>Méditerranée 1, Level 1</td>
<td>Steven Frucht, USA</td>
</tr>
<tr>
<td><strong>2516</strong> Special Topics in Movement Disorders</td>
<td>The Future Is Now: Telemedicine in Your Movement Disorders Practice</td>
<td>18:00 – 19:30</td>
<td>Hermès Auditorium, Level 2</td>
<td>Maria Stamelou, Greece</td>
</tr>
</tbody>
</table>

**Description:**

#### Using Genetic Tools for Diagnosis

- **Location:** Les Muses 3, Level 3
- **CSPC Liaison:** Maria Stamelou, Greece

In this interactive session, the presenters will describe the different tools currently available for the laboratory diagnosis of genetic movement disorders, including tools for the detection of mutations in single genes (including small sequence and copy number variants), as well as gene panels, clinical whole-exome (WES) and whole-genome sequencing (WGS).

At the conclusion of this session, participants should be better able to:
1. Identify currently existing tools for the laboratory diagnosis of genetic movement disorders
2. Recognize the advantages and disadvantages of the different tools
3. Define the strategy of choice for diagnostic genetic testing of patients with movement disorders

**Recommended Audience:** Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

#### Metabolic Movement Disorders

- **Location:** Méditerranée 2, Level 1
- **CSPC Liaison:** Maria Stamelou, Greece

In this interactive session, the presenters will discuss the phenotypic spectrum of movement disorders caused by a variety of metabolic diseases, diagnostic tools to approach metabolic movement disorders and available treatment plans for patients with these disorders.

At the conclusion of this session, participants should be better able to:
1. Interpret the phenotypic spectrum of movement disorders caused by metabolic diseases
2. Describe diagnostic tools for metabolic disease causing movement disorders
3. Design, review and modify a treatment plan for patients with metabolic movement disorders

**Recommended Audience:** Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

#### Atypical Parkinsonism

- **Location:** Athéna Auditorium, Level 2
- **CSPC Liaison:** Ryosuke Takahashi, Japan

In this interactive session, the presenters will explain the clinical diagnostic criteria and red flags for atypical parkinsonism and show videos of the phenomenology of patients with atypical parkinsonism such as progressive supranuclear palsy, corticobasal syndrome, multiple system atrophy and Lewy body disease. The audience will learn important tips to clinically distinguish atypical parkinsonism from Parkinson’s disease.

At the conclusion of this session, participants should be better able to:
1. Detect situations amenable to telemedicine for improving care of patients with movement disorders such as Parkinson’s disease and will describe practical ways in which such telemedicine visits can be implemented in everyday clinical practice
2. Describe ways in which a telemedicine visit can be implemented in clinical practice
3. Identify challenges in telemedicine visits and ways to overcome them

**Recommended Audience:** Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Monday, September 23, 2019

2617  Special Topics in Movement Disorders  (TICKET)

Gait Disorders: From Pathophysiology to the Clinic
18:00 – 19:30
Location: Les Muses 2, Level 3
Klaus Jahn, Germany
Jorik Nonnekes, Netherlands
CSPC Liaison: Alice Nieuwboer, Belgium
In this interactive session, the delegates will gain a better understanding of how different neurological systems are involved in gait and how this presents in clinical practice. Video vignettes will also illustrate how gait deficits can be recognized and how they can be best managed.

At the conclusion of this session, participants should be better able to:
1. Translate a systems understanding of gait disorder into the clinical picture
2. Recognize cerebellar and vestibular contributions to gait disorders and their management
3. Recognize corticostriatal dysfunction in gait disorders and their management
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

2618  Special Topics in Movement Disorders  (TICKET)

Pluripotent Stem Cells and Organoids: State-of-the-Art
18:00 – 19:30
Location: Méditerranée 3, Level 1
Agnete Kirkeby, Denmark
Wim Mandemakers, Netherlands
CSPC Liaison: Vincenzo Bonifati, Netherlands
In this session, the technology of induced pluripotent stem cells (iPS) and brain organoids as powerful tools for disease modeling will be presented, and the potential application of iPS in the experimental therapy of Parkinson’s disease will be discussed.

At the conclusion of this session, participants should be better able to:
1. Illustrate the application of human pluripotent stem cell technology and brain organoids to study mechanisms of movement disorders
2. Discuss the potential of human pluripotent stem cell technology to treat Parkinson’s disease
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

---

Tuesday, September 24, 2019

3101  Plenary Session

Tremor Disorders: Challenges and Future Directions
8:00 – 9:30
Location: Apollon Auditorium, Level 2, 3
Chairs: Kailash Bhatia, United Kingdom
Maria Stamelou, Greece
8:00  Overview of the New Classification Scheme for Tremor
Rodger Elble, USA
8:30  What Do We Know About Etiologies?
Peter Bain, United Kingdom
9:00  Pathophysiology of Tremor: Is Pathophysiology Useful in Diagnosis and Classification?
Rick Helmich, Netherlands
CSPC Liaison: Maria Stamelou, Greece
At the conclusion of this session, participants should be better able to:
1. Apply the new tremor classification scheme in everyday clinical practice
2. Describe how the etiologies of tremor relate to classification
3. Describe how the pathophysiology of tremor relates to the diagnosis and classification of tremor
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

MDS Business Meeting
9:30-10:30
Location: Hermès Auditorium, Level 2
All delegates are encouraged to attend.

3102  Plenary Session

Grand Rounds
10:30 – 12:30
Location: Apollon Auditorium, Level 2, 3
MDS Experts: Tim Anderson, New Zealand
Mathieu Anheim, France
Steven Frucht, USA
Timothy Lynch, Ireland
CSPC Liaison: Jean-Christophe Corvol, France
In this interactive session, MDS experts will examine both common and complex movement disorder patients. The audience will gain expert advice on how to formulate diagnoses and manage interesting and challenging patients.

At the conclusion of this session, participants should be better able to:
1. Identify how experts use the clinical history and exam to formulate a diagnosis
2. Identify how experts use diagnostic testing in the differential diagnosis of movement disorders
3. Identify how experts plan therapies for movement disorder patients
Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Tuesday, September 24, 2019

**3203 Parallel Session**

**Psychosis and Hallucinations in Lewy Body Disorders**

15:30 – 17:30

**Location:** Méditerranée 1, Level 1

**Chairs:** Gilles Fenelon, France
Simon Lewis, Australia

15:30 Current Theories on Visual Hallucinations
Nico Diederich, Luxembourg

16:10 Neuroimaging and Visual Hallucinations: A Window Into Their Mechanism
Simon Lewis, Australia

16:50 Management Strategies for Visual Hallucinations and Psychosis
Laura Marsh, USA

CSPC Liaison: Jennifer Goldman, USA

At the conclusion of this session, participants should be better able to:
1. Identify current theories of visual hallucinations in Parkinson’s disease and Lewy body disorders
2. Describe neuroimaging findings associated with visual hallucinations in Parkinson’s disease and Lewy body disorders
3. Review management strategies for hallucinations and delusions in Parkinson’s disease and Lewy body disorders

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

---

**3204 Parallel Session**

**Challenges in Clinicogenetic Correlations: One Gene - Many Phenotypes; One Phenotype - Many Genes**

15:30 – 17:30

**Location:** Athéna Auditorium, Level 2

**Chairs:** Vincenzo Bonifati, Netherlands
Enza Maria Valente, Italy

15:30 One Gene – Many Phenotypes
Niccolo Mencacci, USA

16:10 One Phenotype – Many Genes
Aurelie Meneret, France

16:50 Clinical Implications – Diagnosis and Management Strategies
Enza Maria Valente, Italy

CSPC Liaison: Vincenzo Bonifati, Netherlands

At the conclusion of this session, participants should be better able to:
1. Recognize the sometimes different and complex phenotypes of monogenic mutations
2. Describe similar clinical phenotypes resulting from mutations in different genes
3. Discuss the evolving role of genetics in the diagnosis and management of movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

---

**3205 Parallel Session**

**Myoclonus**

15:30 – 17:30

**Location:** Apollon Auditorium, Level 2, 3

**Chairs:** Marina De Koning-Tijssen, Netherlands
Steven Frucht, USA

15:30 The Essential Role of Physiology in Understanding and Evaluating Myoclonus
Hiroshi Shibasaki, Japan

16:10 The Progressive Myoclonic Epilepsies: How Genetics Have Revolutionized Understanding of These Disorders
Pierre Genton, France

16:50 Treatment of Myoclonus: What Is the Evidence?
Martje Van Egmond, Netherlands

CSPC Liaison: Steven Frucht, USA

At the conclusion of this session, participants should be better able to:
1. Explain the role of physiology in the evaluation and management of myoclonus
2. Appreciate the enormous strides made in understanding genetic forms of myoclonus
3. Review the evidence supporting decisions on treatments for myoclonus

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

---

**3206 Parallel Session**

**Translational Science of Dystonia**

15:30 – 17:30

**Location:** Méditerranée 2, Level 1

**Chairs:** William Dauer, USA
Marie Vidailhet, France

15:30 How Genetics, Cell Biology and Animal Models Informed Our Understanding of Dystonia
William Dauer, USA

16:10 Dystonia as a Network Disorder: How Physiology and Imaging Have Informed Our Understanding of Dystonia
Ryuji Kaji, Japan

16:50 The Mystery of Deep Brain Stimulation in Dystonia: Are We Any Closer to Understanding How it Works?
Jill Ostrem, USA

CSPC Liaison: Carolyn Sue, Australia

At the conclusion of this session, participants should be better able to:
1. Discuss the role that advances in the basic sciences have played in our understanding of dystonia
2. Summarize the role that imaging and physiology have played in understanding the biological bases for dystonia
3. Analyze the current theories explaining the improvement of dystonia with Deep Brain Stimulation

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
# Tuesday, September 24, 2019

## 3207 Parallel Session
### Drug Repurposing in Parkinson’s Disease
**15:30 – 17:30**
**Location:** Méditerranée 3, Level 1
**Chairs:** Wassilios Meissner, France
D. James Surmeier, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30</td>
<td>Recent and Ongoing Clinical Trials with Repurposed Drugs</td>
</tr>
<tr>
<td></td>
<td>Michael Schwarzschild, USA</td>
</tr>
<tr>
<td>16:10</td>
<td>Repurposing Anti-Hypertensive Drugs: Rationale and Clinical Experience</td>
</tr>
<tr>
<td></td>
<td>Tatyana Simuni, USA</td>
</tr>
<tr>
<td>16:50</td>
<td>Insulin Resistance and Diabetes: Repurposing Antidiabetics as Disease Modifying Treatments</td>
</tr>
<tr>
<td></td>
<td>Wassilios Meissner, France</td>
</tr>
</tbody>
</table>

**CSPC Liaison:** Angela Cenci, Sweden

At the conclusion of this session, participants should be better able to:
1. Critically review recent clinical studies for Parkinson’s disease involving inosine, nilotinib, simvastatin, and iron chelators
2. Summarize scientific rationale and clinical study of isradipine for disease modification in Parkinson’s disease
3. Discuss the scientific rationale for repurposing antidiabetics as potential disease-modifying treatments for Parkinson’s disease

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

## 3308 Science of Industry Session (non-CME)

See page 21 for complete session information.

## 3309 Teaching Course
### Recognition and Management of Sleep Disturbances in Movement Disorders
**15:30 – 17:30**
**Location:** Les Muses 1, Level 3
**Chairs:** Ron Postuma, Canada
Aleksandar Videnovic, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30</td>
<td>Insomnia and Somnolence in Movement Disorders</td>
</tr>
<tr>
<td></td>
<td>Aleksandar Videnovic, USA</td>
</tr>
<tr>
<td>16:10</td>
<td>Restless Legs Syndrome in Movement Disorders</td>
</tr>
<tr>
<td></td>
<td>Juliane Winkelmann, Germany</td>
</tr>
<tr>
<td>16:50</td>
<td>Parasomnias and Sleep-Related Breathing Disorders in Movement Disorders</td>
</tr>
<tr>
<td></td>
<td>Ron Postuma, Canada</td>
</tr>
</tbody>
</table>

**CSPC Liaison:** Wassilios Meissner, France

At the conclusion of this session, participants should be better able to:
1. Discuss the management of insomnia and excessive daytime sleepiness in movement disorders
2. Discuss the management of restless legs syndrome in movement disorders
3. Analyze investigations and therapeutic options for parasomnias and sleep-related breathing disorders in movement disorders

**Recommended Audience:** Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

## 3310 Teaching Course
### Pediatric Movement Disorders
**15:30 – 17:30**
**Location:** Les Muses 2, Level 3
**Chairs:** Manju Kurian, United Kingdom
Ali Shalash, Egypt

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30</td>
<td>Transient Benign Movement Disorders of Infancy</td>
</tr>
<tr>
<td></td>
<td>Emilio Fernandez-Alvarez, Spain</td>
</tr>
<tr>
<td>16:10</td>
<td>Genetic Movement Disorders in Children and Adolescents</td>
</tr>
<tr>
<td></td>
<td>Manju Kurian, United Kingdom</td>
</tr>
<tr>
<td>16:50</td>
<td>Acquired Movement Disorders in Children and Adolescents</td>
</tr>
<tr>
<td></td>
<td>Darius Ebrahimi-Takahari, USA</td>
</tr>
</tbody>
</table>

**CSPC Liaison:** Wassilios Meissner, France

At the conclusion of this session, participants should be better able to:
1. Recognize transient benign movement disorders in infancy
2. Summarize genetic movement disorders in children and adolescents
3. Illustrate acquired movement disorders in children and adolescents

**Recommended Audience:** Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

## 3411 Skills Workshop
### Allied Health Professionals’ Skills for Proactive Patient Management
**18:00 – 19:30**
**Location:** Méditerranée 2, Level 1
**Chairs:** Terry Ellis, USA
Sue Thomas, United Kingdom

**CSPC Liaison:** Alice Nieuwboer, Belgium

In this interactive session, the presenters will focus on how to assess and manage Parkinson’s disease patients proactively to maintain optimal levels of subjective well-being. The audience will learn about the benefits of involving nurses and physical therapists in patient care and learn about the timely interventions of each profession to prevent disease-related complications.

At the conclusion of this session, participants should be better able to:
1. Identify the most optimal management strategies to prevent Parkinson’s disease-related complications in various disease stages
2. Define the role of the Parkinson’s disease nurse in realizing proactive patient care
3. Explain methods to enhance exercise compliance and physical activity levels in Parkinson’s disease

**Recommended Audience:** Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Tuesday, September 24, 2019

### 3412 Skills Workshop

**Clinical Applications of Big Data Analytics in Movement Disorders: Challenges, Promises and Potentials**

18:00 – 19:30

**Location:** Apollon Auditorium, Level 2, 3
Jean-Christophe Corvol, France
Charles Venuto, USA

**CSPC Liaison:** Roongroj Bhidayasiri, Thailand

In this session, the presenters will describe the nascent field of big data analytics in movement disorders, discuss the benefits as well as limitations, outline methodologies and applications on how to integrate small data sets. Examples with clinical applications will be provided (e.g. genetics and imaging). The presenters will briefly discuss challenges and offer recommendations for the future.

At the conclusion of this session, participants should be better able to:
1. Define advantages and challenges of big data analytics in movement disorders
2. Describe architectural framework of big data analytics through the process of application, development, and methodology
3. Evaluate examples of big data analytics in movement disorders (especially Parkinson's disease) with their clinical applications

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

### 3413 Skills Workshop

**Monogenic Hyperkinetic Disorders with Variable Phenotypes**

18:00 – 19:30

**Location:** Méditerranée 3, Level 1
Martin Paucar Arce, Sweden
Ana Westenberger, Germany

**CSPC Liaison:** Vincenzo Bonifati, Netherlands

In this interactive session, the presenters will describe the pleomorphic phenotypes associated with ATP1A3, ADCY5, and PDE10A and other related genes, as well as the underlying genotypes, and they will discuss how these rare monogenic movement disorders might provide insights for understanding normal brain functions and the pathogenesis of more common forms of complex movement disorders.

At the conclusion of this session, participants should be better able to:
1. Discuss disorders associated with mutations in the ATP1A3, ADCY5, and PDE10A gene variants
2. Illustrate the underlying genetic variants and emerging genotype-phenotype correlations
3. Discuss possible insights deriving from these rare monogenic forms for understanding of normal brain functions and the pathogenesis of more common movement disorders

**Recommended Audience:** Basic scientists, Clinical academicians, Students/Residents/Trainees

### 3414 Skills Workshop

**Eye Movements: A Case-Based Approach**

18:00 – 19:30

**Location:** Les Muses 1, Level 3
Vivek Lal, USA
Aasef Shaikh, USA

**CSPC Liaison:** Roongroj Bhidayasiri, Thailand

In this interactive session, delegates will acquire clinical ophthalmologic examination skills, focusing on eye movement examinations, to recognize typical abnormalities and to integrate these findings into a differential diagnosis of movement disorder conditions.

At the conclusion of this session, participants should be better able to:
1. Describe the approach to a bedside neuro-ophthalmological exam in movement disorders
2. Recognize typical eye movement abnormalities in common hypokinetic and hyperkinetic disorders
3. Integrate findings from bedside ophthalmological examinations into differential diagnosis of movement disorders

**Recommended Audience:** Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

### 3415 Skills Workshop

**A Case-Based Approach for Management of Motor Fluctuations and Dyskinesias**

18:00 – 19:30

**Location:** Méditerranée 1, Level 1
Han-Joon Kim, South Korea
Fabrizio Stocchi, Italy

**CSPC Liaison:** Maria Stamelou, Greece

In this interactive session, the faculty will describe the clinical phenomenology of both motor fluctuations and dyskinesias in Parkinson's disease, along with current and potential future treatment strategies.

At the conclusion of this session, participants should be better able to:
1. Describe the various types of motor fluctuations in Parkinson's disease
2. Describe the various types of dyskinesias in Parkinson's disease
3. Summarize treatment strategies for motor fluctuation and dyskinesias

**Recommended Audience:** Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Tuesday, September 24, 2019

**3516 Video Session**  
**Movement Disorder Emergencies**  
18:00 – 19:30  
Location: Les Muses 2, Level 3  
Roongroj Bhidayasiri, Thailand  
Anna Castrioto, France  
CSPC Liaison: Shen-Yang Lim, Malaysia  

*In this interactive session, the presenters will show videos of hypokinetic and hyperkinetic emergencies, and outline the management strategies for these conditions.*  

At the conclusion of this session, participants should be better able to:  
1. Recognize clinical settings and signs of movement disorder emergencies, including emergencies related to Deep Brain Stimulation  
2. Explain management strategies for the various Parkinson’s disease related and other hypokinetic emergencies  
3. Describe management strategies for the various hyperkinetic emergencies  

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

**3617 Special Topics in Movement Disorders**  
**Axial Movement Disorders: Camptocormia, Pisa Syndrome, Antecollis, and Retrocollis**  
18:00 – 19:30  
Location: Athéna Auditorium, Level 2  
Günther Deuschl, Germany  
Michele Tinazzi, Italy  
CSPC Liaison: H.A. Jinnah, USA  

*In this session, faculty will describe axial defects in Parkinson’s disease and other movement disorders including their clinical manifestations, pathophysiology and treatment.*  

At the conclusion of this session, participants should be better able to:  
1. Describe the varied clinical manifestations of postural abnormalities in various movement disorders  
2. Discuss possible mechanisms of postural problems in various movement disorders  
3. Summarize avenues for management of postural problems in various movement disorders  

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

**3618 Special Topics in Movement Disorders**  
**How to Become a Successful Movement Disorder Specialist**  
18:00 – 19:30  
Location: Les Muses 3, Level 3  
Yves Agid, France  
Caroline Tanner, USA  
CSPC Liaison: Roland Dominic Jamora, Philippines  

*In this interactive session, the presenters will discuss the approach to becoming a successful movement disorder specialist in academic and private practice settings.*  

At the conclusion of this session, participants should be better able to:  
1. Recognize the best approach to becoming an excellent movement disorder specialist in academic medicine and in the clinic  
2. Recognize the importance of searching for good mentors when pursuing specialization  
3. Identify essential aspects of becoming an effective leader  

Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

**European National Society Networking Event**  
19:30 – 20:30  
Location: Mykonos Lounge, Level 2  

This is a networking event for MDS-ES leaders and representatives from European National Societies.

**Health Professionals Networking Meeting**  
19:30 – 20:30  
Location: Galliéni 1+2, Level 2  

Join the MDS Health Professionals (Non-Physician) Special Interest Group (SIG) as they discuss exciting updates going on around the world, meet the SIG Leadership, and discuss current trends in the field.

**Young Delegates Networking Event**  
19:30 – 21:30  
Location: Le Palace (about 600m away from the Nice Acropolis Convention Centre)  

All young delegates at the International Congress are invited to attend this event. It is located within walking distance of the Convention Centre.
Wednesday, September 25, 2019

4101 Plenary Session

Predicting Parkinson's Disease Onset and Progression
8:00 – 9:30
Location: Apollon Auditorium, Level 2, 3
Chairs: Jean-Christophe Corvol, France
Matthew Stern, USA

8:00 What Can Big Cohorts Add to Prediction for Parkinson's Disease?
Andrew Siderowf, USA
8:30 Precision Medicine: Insights from Genetic and Other Biomarkers
Rejko Krueger, Luxembourg
9:00 Sleep and Parkinson's Disease: Prediction and Progression
Friederike Sixel-Doring, Germany

CSPC Liaison: Jean-Christophe Corvol, France

At the conclusion of this session, participants should be better able to:
1. Discuss implications of results from big cohorts in predicting onset or progression of Parkinson's disease
2. Discuss the role of genetic and other biomarkers in predicting onset or progression of Parkinson's disease
3. Identify the predictive value of sleep disorders in predicting onset or progression of Parkinson's disease

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4102 Plenary Session

Autoimmune Movement Disorders: From Phenomenology to Immunopathogenesis
10:00 -12:00
Location: Apollon Auditorium, Level 2, 3
Chairs: Victor Fung, Australia
Jerome Honnorat, France

10:00 How Do I Recognize an Autoimmune Movement Disorder?
Sarosh Irani, United Kingdom
10:40 The Pathogenesis of Autoimmune Movement Disorders
Angela Vincent, United Kingdom
11:20 Therapeutic Approaches to Autoimmune Movement Disorders
Sean Pittcock, USA

CSPC Liaison: Carolyn Sue, Australia

At the conclusion of this session, participants should be better able to:
1. Describe the clinical clues for autoimmune movement disorders
2. Explain the molecular mechanisms of autoimmune movement disorders
3. Summarize therapeutic approaches for autoimmune movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4203 Parallel Session

Placebos in Parkinson’s Disease and Other Movement Disorders
15:00 – 17:00
Location: Méditerranée 3, Level 1
Chairs: Christopher Goetz, USA
Olivier Rascol, France

15:00 The Science of Placebo
Fabrizio Benedetti, Italy
15:40 Assessing Placebo Response in Clinical Trials
Joaquim Ferreira, Portugal
16:20 Harnessing the Power of Placebos in Clinical Practice and Research
Tiago Mestre, Canada

CSPC Liaison: Jean-Christophe Corvol, France

At the conclusion of this session, participants should be better able to:
1. Discuss the scientific basis for the placebo response and related effects
2. Recognize the nature and underpinnings of the placebo and nocebo responses
3. Apply the novel perspectives on the use of placebos in research and clinical practice

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4204 Parallel Session

Huntington’s Disease: From Bench to Bedside
15:00 – 17:00
Location: Les Muses 1, Level 3
Chairs: Sandrine Humbert, France
Karen Marder, USA

15:00 The Many Presentations of Huntington’s Disease and the Differential Diagnosis
Claudia Perandones, Argentina
15:40 The Role of Huntington in Neurodegeneration and Neurodevelopment: What Have We Learned?
Sandrine Humbert, France
16:20 Current and Future Therapies for Huntington’s Disease
Sarah Tabrizi, United Kingdom

CSPC Liaisons: Emilia Gatto, Argentina
Karen Marder, USA

At the conclusion of this session, participants should be better able to:
1. Recognize the many variable phenotypes of Huntington’s disease and potential differential diagnosis
2. Identify the genetic mechanisms underlying Huntington’s disease
3. Identify the current and new therapies for Huntington’s disease

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Wednesday, September 25, 2019

4205 Parallel Session **TICKET**

**How to Diagnose Rare Movement Disorders**
15:00 – 17:00
Location: Apollon Auditorium, Level 2, 3
Chairs: Emilia Gatto, Argentina
Pedro Garcia Ruiz, Spain
15:00 Clinical Clues for Rare Movement Disorders
Pramod Pal, India
15:40 Laboratory Clues for Rare Movement Disorders
Emilia Gatto, Argentina
16:20 Neuroimaging Clues for Rare Movement Disorders
Pedro Garcia Ruiz, Spain

CSPC Liaison: Shen-Yang Lim, Malaysia
At the conclusion of this session, participants should be better able to:
1. Recognize clinical features of rare movement disorders
2. Discuss laboratory tests for rare movement disorders
3. Describe imaging findings of rare movement disorders
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4206 Parallel Session **TICKET**

**Spasticity: From Bench to Bedside**
15:00 – 17:00
Location: Méditerranée 1, Level 1
Chairs: Mark Hallett, USA
Raymond Rosales, Philippines
15:00 Recognition and Differential Diagnosis of Spasticity: Hereditary and Acquired
Joerg Wissel, Germany
15:40 The Molecular and Physiological Basis for Spasticity
Craig Blackstone, USA
16:20 Recent Advances in the Management of Spasticity
Jean-Michel Gracies, France

CSPC Liaison: H.A. Jinnah, USA
At the conclusion of this session, participants should be better able to:
1. Report the various clinical presentations and differential diagnosis of spasticity
2. Describe the biological basis for spasticity at the molecular and physiological levels
3. Summarize management options for spasticity
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4207 Parallel Session **TICKET**

**Translating Genetic Discoveries into Disease-Modifying Strategies for Parkinson’s Disease**
15:00 – 17:00
Location: Les Muses 2, Level 3
Chairs: Alexis Brice, France
Mark Cookson, USA
15:00 Strategies Targeting Mitochondria
Ryan Davis, Australia
15:40 Is LRRK2 Inhibition a Viable Disease-Modifying Strategy?
Mark Cookson, USA
16:20 Strategies for Disease-Modification Targeting GBA
Ziv Gan-Or, Canada

CSPC Liaison: Vincenzo Bonifati, Netherlands
At the conclusion of this session, participants should be better able to:
1. Compare the different strategies targeting mitochondria for Parkinson's disease
2. Discuss LRRK2 kinase inhibition as a strategy for Parkinson’s disease
3. Compare the different strategies, targeting the glucocerebrosidase enzyme for Parkinson’s disease
Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

4208 Parallel Session **TICKET**

**Dyskinesia in Parkinson's Disease: From the Bedside to the Lab Bench**
15:00 – 17:00
Location: Les Muses 3, Level 3
Chairs: Angelo Antonini, Italy
Philippe Damier, France
15:00 Update on the Clinical Phenomenology and Burden of Dyskinesias
Oscar Gerchak, Argentina
15:40 Modulation of Dopamine Signaling by Glutamate and Serotonin Receptors
Angela Cenci Nilsson, Sweden
16:20 Morphological and Functional Changes of Striatal and Cortical Neurons
Masahiko Tomiyama, Japan

CSPC Liaison: Angela Cenci, Sweden
At the conclusion of this session, participants should be better able to:
1. Review the incidence and clinical features of dyskinesias in Parkinson's disease, and their impact on activities of daily living
2. Appraise the mechanisms by which glutamate and serotonin receptors can modulate an altered dopamine signaling in dyskinesias
3. Summarize the evidence that dyskinesias relate to maladaptive changes of dendritic spines in striatal and cortical neurons
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Wednesday, September 25, 2019

**4309 Teaching Course [Ticket]**

**Recognition and Management of Non-Motor Symptoms in Parkinson's Disease**

15:00 – 17:00

Location:  Athéna Auditorium, Level 2

Chairs:  Bastiaan Bloem, Netherlands
        K. Ray Chaudhuri, United Kingdom

15:00 Recognition and Management of Neuropsychiatric Disorders
Daniel Weintraub, USA

15:40 Recognition and Management of Dysautonomia
Alessandra Fanciulli, Austria

16:20 Recognition and Management of Pain and Fatigue
K. Ray Chaudhuri, United Kingdom

CSPC Liaison: Wassilios Meissner, France

At the conclusion of this session, participants should be better able to:

1. Describe the recognition and management of neuropsychiatric disorders in Parkinson's disease
2. Summarize the recognition and management of dysautonomia in Parkinson's disease
3. Discuss the recognition and management of pain and fatigue in Parkinson's disease

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

**4310 Teaching Course [Ticket]**

**Palliative Care for Parkinson’s Disease**

15:00 – 17:00

Location:  Méditerranée 2, Level 1

Chairs:  Nicholas Galifianakis, USA
        Victor McConvey, Australia

15:00 Definition and Models of Palliative Care
Stefan Lorenzl, Germany

15:40 Managing Palliative Needs of Patients and Their Caregivers
Nicholas Galifianakis, USA

16:20 End-of-Life Care
Miguel Coelho, Portugal

CSPC Liaison: Wassilios Meissner, France

At the conclusion of this session, participants should be better able to:

1. Define palliative care for Parkinson’s disease
2. Manage palliative needs of patients with Parkinson’s disease and their caregivers
3. Examine the management of end-of-life for Parkinson’s disease

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

**4411 Skills Workshop, cont. [Ticket]**

**Practical Use of the MDS-UPDRS**

17:30 – 19:00

Location:  Les Muses 3, Level 3

Evžen Růžička, Czech Republic
Glenn Stebbins, USA

CSPC Liaison: Christopher Goetz, USA

**4412 Skills Workshop [Ticket]**

**Recognition and Management of Non-Motor Symptoms in Parkinson’s Disease**

15:00 – 17:00

Location:  Athéna Auditorium, Level 2

Chairs:  Bastiaan Bloem, Netherlands
        K. Ray Chaudhuri, United Kingdom

15:00 Recognition and Management of Neuropsychiatric Disorders
Daniel Weintraub, USA

15:40 Recognition and Management of Dysautonomia
Alessandra Fanciulli, Austria

16:20 Recognition and Management of Pain and Fatigue
K. Ray Chaudhuri, United Kingdom

CSPC Liaison: Wassilios Meissner, France

At the conclusion of this session, participants should be better able to:

1. Describe the recognition and management of neuropsychiatric disorders in Parkinson’s disease
2. Summarize the recognition and management of dysautonomia in Parkinson’s disease
3. Discuss the recognition and management of pain and fatigue in Parkinson’s disease

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

**4413 Skills Workshop [Ticket]**

**Functional (Psychogenic) Movement Disorders**

17:30 – 19:00

Location:  Apollon Auditorium, Level 2, 3

Isabel Parees, Spain
Jon Stone, United Kingdom

CSPC Liaison: Beomseok Jeon, South Korea

In this interactive session, the presenters will discuss how to effectively communicate about the diagnosis and management in patients with functional movement disorders. They will discuss novel/experimental treatments.

At the conclusion of this session, participants should be better able to:

1. Deliver an effective diagnostic explanation for functional movement disorders
2. Describe the approach for triaging patients for appropriate therapies
3. Interpret the nature of and role for novel/experimental treatments in functional movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

**4414 Skills Workshop**

**Neuromodulation for Movement Disorders: A Case-Based Approach**

17:30 – 19:00

Location:  Les Muses 1, Level 3

Joohi Jimenez-Shahed, USA
Genko Oyama, Japan

CSPC Liaison: Elena Moro, France

In this interactive session, the audience will be involved in the discussion of the selection and treatment of difficult movement disorders cases with neuromodulation therapies. Participants will be able to recognize and learn how to manage several types of complications and side effects in patients treated with neuromodulation.

At the conclusion of this session, participants should be better able to:

1. Identify common and uncommon issues in neuromodulation therapies
2. Manage side effects and complications related to neuromodulation therapies
3. Summarize the rational steps to optimize neuromodulation therapies

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Wednesday, September 25, 2019

4414 Skills Workshop [TICKET]
Botulinum Toxins: Difficult Cases and Pitfalls
17:30 – 19:00
Location:  Athéna Auditorium, Level 2
Austen Peter Moore, United Kingdom
Raymond Rosales, Philippines
CSPC Liaison: Roland Dominic Jamora, Philippines
This interactive session will present potential pitfalls in the treatment of movement disorders with botulinum toxins, along with management strategies for problems that are more difficult to treat.

At the conclusion of this session, participants should be better able to:
1. Recognize potential pitfalls in the application of botulinum toxins in clinical practice
2. Identify situations when botulinum toxin should not be used
3. Analyze strategies to manage difficult cases and improve outcome in botulinum toxin use

Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

4515 Video Session [TICKET]
Lessons From My Patients
17:30 – 19:00
Location:  Méditerranée 2, Level 1
Francisco Cardoso, Brazil
Janet Rucker, USA
CSPC Liaisons: Shengdi Chen, People’s Republic of China
Steven Frucht, USA
In this interactive session, experienced faculty will describe some of the important lessons they have learned from their patients. The discussion will focus on misleading presentations in some cases, the complexity of individualizing care, and the role that patients sometimes play in reaching a correct diagnosis or treatment strategy.

At the conclusion of this session, participants should be better able to:
1. Recognize unusual and sometimes misleading presentations of movement disorders
2. Discuss the complexity of delivering individualized patient care
3. Describe the role patients play in educating their physicians

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4516 Video Session [TICKET]
Video Demonstration of Pediatric Movement Disorders
17:30 – 19:00
Location:  Méditerranée 1, Level 1
Mirjam Carecchio, Italy
Rose Pons, Greece
CSPC Liaison: Maria Stamelou, Greece
In this interactive session, the presenters will demonstrate with illustrative videos the wide phenotypic spectrum of pediatric movement disorders and their evolution into adulthood. The audience will also observe video cases of potentially treatable pediatric movement disorders that are important not to miss.

At the conclusion of this session, participants should be better able to:
1. Describe the phenotypic spectrum of movement disorders in children
2. Recognize the evolution of pediatric movement disorders into adulthood
3. Determine potentially treatable pediatric movement disorders

Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

4617 Special Topics in Movement Disorders [TICKET]
Sleep Disorders: REM Sleep Behavior Disorder
17:30 – 19:00
Location:  Méditerranée 3, Level 1
Michael Howell, USA
Michele Hu, United Kingdom
CSPC Liaison: Claudia Trenkwalder, Germany
In this interactive session the presenters will give insights into RBD symptoms, showing videos, defining the risk factors for prodromal Parkinson’s disease and discussing the future role of RBD for clinical trials, focused on the problems of conversion from RBD.

At the conclusion of this session, participants should be better able to:
1. Identify the clinical symptomatology of RBD and its assessment
2. Illustrate the evolution of RBD into alpha-synucleinopathies
3. Define the role of RBD for potential therapeutic trials

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4618 Special Topics in Movement Disorders [TICKET]
Normal Pressure Hydrocephalus for Movement Disorders Neurologists
17:30 – 19:00
Location:  Les Muses 2, Level 3
Alfonso Fasano, Canada
Joachim Krauss, Germany
CSPC Liaison: Beomseok Jeon, South Korea
In this interactive session, the presenters will discuss clinical features, diagnostic tools, surgery and their limitations in diagnosing and managing normal pressure hydrocephalus.

At the conclusion of this session, participants should be better able to:
1. Describe the clinical features and tools useful for diagnosis and differential diagnosis of normal pressure hydrocephalus
2. Describe the heterogeneity and pathophysiological dilemmas of normal pressure hydrocephalus
3. Select and inform possible surgical candidates for shunting

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

MDS Video Challenge Pre-Event Gathering
19:00 – 20:00
Location:  Agora 2 and Agora 3, Level 2, 3

MDS Video Challenge
20:00 – 22:00
Location:  Apollon Auditorium, Level 2, 3
MDS Experts: Stewart Factor, USA
Manju Kurian, United Kingdom
Tiago Mestre, Canada
Francesca Mongi, United Kingdom
Martin Paucar Arce, Sweden
See page 27 for more information.

Final Program • www.mdscongress.org  19
Thursday, September 26, 2019

5101 Themed Plenary Session

**Synuclein in Parkinson’s Disease and Atypical Parkinsonism: From Bench to Bedside**

8:00 – 9:30

*Location:* Apollon Auditorium, Level 2, 3
*Chairs:* Etienne Hirsch, France
Werner Poewe, Austria

8:00 Is Synucleinopathy a Single Entity?  
Glenda Halliday, Australia

8:30 Pathogenic Spreading in the Synucleinopathies  
Erwan Bezdard, France

9:00 Clinical Trials in Synucleinopathies  
Brit Mollenhauer, Germany

*CSPC Liaison:* Etienne Hirsch, France

At the conclusion of this session, participants should be better able to:
1. Analyze the clinical and pathological features of Parkinson’s disease and atypical parkinsonism
2. Debate the role of α-synuclein in the initiation and progression of Parkinson’s disease and atypical parkinsonism
3. Summarize new clinical trials for synucleinopathies

*Recommended Audience:* Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

5102 Plenary Session

**Controversies in Movement Disorders**

10:00 – 11:00

*Location:* Apollon Auditorium, Level 2, 3
*Chairs:* Oscar Gershanik, Argentina
Antonio Strafella, Canada

10:00 Is There a Role for Cannabinoids in Movement Disorders?  
(YES)  
Benzi Kluger, USA

10:15 Is There a Role for Cannabinoids in Movement Disorders?  
(NO)  
Janis Miyasaki, Canada

10:30 Early Deep Brain Stimulation in Parkinson’s Disease?  
(YES)  
Patricia Limousin, United Kingdom

10:45 Early Deep Brain Stimulation in Parkinson’s Disease?  
(NO)  
Beomseok Jeon, South Korea

*CSPC Liaison:* Antonio Strafella, Canada

At the conclusion of this session, participants should be better able to:
1. Debate the advantages and disadvantages of cannabinoids in movement disorders
2. Debate the advantages and disadvantages of early Deep Brain Stimulation in Parkinson’s disease

*Recommended Audience:* Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

5103 Plenary Session

**Highlights for 2019: Looking Towards 2020**

11:00 – 12:00

*Location:* Apollon Auditorium, Level 2, 3
*Chairs:* Vincenzo Bonifati, Netherlands
Christopher Goetz, USA

11:00 Basic Sciences  
Etienne Hirsch, France

11:30 Clinical Sciences  
Claudia Trenkwalder, Germany

*CSPC Liaisons:* Vincenzo Bonifati, Netherlands
Claudia Trenkwalder, Germany

At the conclusion of this session, participants should be better able to:
1. Critically review high impact scientific discoveries from the past year and important areas of scientific focus for 2020 research
2. Critically review high impact clinical studies from the past year and important ongoing trials with anticipated completion in 2020

*Recommended Audience:* Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Non-CME Educational Activities

NEW - Science of Industry Session (non-CME)
These interactive sessions will provide delegates with a non-CME educational opportunity to learn about novel therapeutic agents under development by industry. Sessions may incorporate basic scientists or clinicians working in industry, and topics may address the biological rationale or development process for specific therapeutics in development within the field of Movement Disorders.

Monday, September 23, 2019

2205 Science of Industry Session (non-CME)

Novel Treatment Strategies for Rare Movement Disorders
15:30 – 17:30
Location: Méditerranée 3, Level 1
Chairs: David Devos, France
        H.A. Jinnah, USA
15:30 PKAN: A Comparison of Multiple Potential Mechanisms and Treatment Strategies for Addressing the Biochemical Defect
        Thomas Klopstock, Germany
16:10 GLUT1: A Comparison of Treatment Strategies for Bypassing the Glucose Transporter Defect
        Emmanuel Roze, France
16:50 Reducing Brain Iron in Degenerative Disorders
        Massimo Pandolfo, Belgium
CSPC Liaison: H.A. Jinnah, USA
At the conclusion of this session, participants should be better able to:
1. Describe the biological rationale for new drugs being developed to address the underlying biochemical defect in pantothenatekinase-associated neurodegeneration
2. Compare the biological basis and clinical outcomes for different treatment strategies being used for GLUT1-related disorders
3. Summarize the biological rationale and clinical outcomes for treatment strategies focusing on reducing brain iron in movement disorders
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

Tuesday, September 24, 2019

3208 Science of Industry Session (non-CME)

Translating Scientific Discovery into Novel Treatments for Movement Disorders
15:30 – 17:30
Location: Les Muses 3, Level 3
Chairs: Stanley Fahn, USA
        H.A. Jinnah, USA
15:30 How Does Industry Decide Which Scientific Discoveries to Pursue?
        Jesse Cedarbaum, USA
16:10 Targeting LRRK2 for Parkinson’s Disease
        Carole Ho, USA
16:50 The Biology of Pathological Oscillations in the Brain: Potential Novel Targets for Tremor Disorders?
        Margaret Lee, USA
CSPC Liaison: H.A. Jinnah, USA
At the conclusion of this session, participants should be better able to:
1. Summarize the criteria used by industry to pursue clinical development of scientific discoveries
2. Describe the pathogenesis of LRRK2-related Parkinson’s disease and its rationale as a therapeutic target
3. Describe how understanding the biological basis for neuronal oscillations points to novel therapeutics for tremor disorders
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees
Corporate Therapeutic Symposia Schedule

These company-based informational sessions provide delegates with non-CME educational opportunities to learn the latest in therapeutics.

**Sunday, September 22**

**Britannia Pharmaceuticals Ltd**
The Time is NOW. Do Our Current Treatment Decisions Ensure PD Patients Live Their Best Lives?
13:15-14:15
Location: Méditerranée 1, Level 1

**Sunovion Pharmaceuticals Inc.**
Debating Therapeutic Advancements in Parkinson’s Disease: Are You a Realist or an Idealist?
13:15-14:15
Location: Méditerranée 2, Level 1

**Monday, September 23**

**Bial**
Beyond Motor Wearing-Off: What Are We Missing?
12:45-13:45
Location: Les Muses 1, Level 3

**Biogen**
Differentiating PSP
12:45-13:45
Location: Méditerranée 2, Level 1

**Zambon**
Safinamide: From Pre-Clinical Data to Real World Evidence
12:45-13:45
Location: Les Muses 2, Level 3

**Tuesday, September 24**

**AbbVie, Inc.**
Shining a Light: Early Recognition of Advanced Parkinson’s Disease and Real-World Considerations for Treatment Options
12:45-13:45
Location: Les Muses 1, Level 3

**Acorda Therapeutics**
Rethinking the Approach to Managing Off Periods
12:45-13:45
Location: Les Muses 2, Level 3

**Roche**
One Thing in Mind, Protecting What Makes Us Who We Are
12:45-13:45
Location: Méditerranée 1, Level 1

The International Parkinson and Movement Disorder Society acknowledges Veritable LP for their assistance in managing its investment portfolio.
Abstract Information

Abstract Publication

All regular accepted abstracts are published as a supplement to the MDS Journal and are available utilizing a searchable feature on the International Congress website, www.mdscongress.org/Congress-2019/Abstracts.htm, as of September 21, 2019. Please also visit www.movementdisorders.org to access Movement Disorders, where a PDF of accepted abstracts can be downloaded.

All registered International Congress delegates will also receive the published abstracts on a USB, available for pickup at the Poster Information Desk at Agora 3 West, Level 3 during regular Congress hours.

Late-Breaking Abstracts and MDS Study Group Abstracts are published as an online supplement on the International Congress website, www.mdscongress.org/Congress-2019/Abstracts.htm. These abstracts are available for download as of September 21, 2019.

Guided Poster Tours

Guided Poster Tours give groups of delegates an opportunity to hear discussion on a select group of abstracts in several sub-categories.

Late-Breaking Abstracts

All accepted Late-Breaking Abstract posters are displayed in Agora 2 South, Level 2, Monday - Wednesday of the International Congress. Late-Breaking abstract poster presentations will take place Wednesday, September 25, from 13:15 - 14:45.

MDS Study Group Abstracts

Abstracts presented on behalf of an MDS Study Group, or formal MDS Task Force or Committee, are indicated with special signage and displayed throughout the poster areas during the scheduled poster sessions.

Poster Sessions

Poster sessions give each delegate an opportunity to view their colleagues’ posters on the most current research in the field of Movement Disorders. Authors will be present for 90 minutes to explain their work and answer questions. All accepted abstracts are presented as a poster at the 2019 International Congress.

Basic Science abstracts will be flagged within each category.

Poster sessions are held Monday - Wednesday. Posters are available for viewing in Agora 2, Agora 3, Les Muses and Les Muses Terrace, from 8:00 – 17:30 Monday and Tuesday, and 8:00 – 17:00 on Wednesday. Poster session topics and schedules vary by date; please see the complete listing of scheduled poster presentation dates and times on page 24.

Become a Member of MDS

MDS Associate Membership Program

Non-members attending the International Congress have the opportunity to receive membership with MDS absolutely free for a year. To sign up today, stop by the MDS Member Center or e-mail membership@movementdisorders.org for more information.

MDS Benefits Include:

- Peer Reviewed Journals: Movement Disorders and Movement Disorders Clinical Practice
- Quarterly Newsletter: Moving Along
- Reduced Course Registration Rates
- Online Resources: CME Activities; Streaming Content; Teaching Slides; Training Videos; and a Video Library with over 2,000 searchable videos

Join over 8,500 professionals across the globe in working to disseminate knowledge and promote research to advance the field.

www.movementdisorders.org/associate-membership
## Poster Session Schedule

<table>
<thead>
<tr>
<th>Poster Numbers</th>
<th>Abstract Category</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 - 56</td>
<td>Huntington's Disease</td>
<td>Agora 3 West, Level 3</td>
</tr>
<tr>
<td>57 - 231</td>
<td>Clinical Trials, Pharmacology and Treatment</td>
<td>Agora 3, Level 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Les Muses, Level 3</td>
</tr>
<tr>
<td>232 - 295</td>
<td>Ataxia</td>
<td>Les Muses, Level 3</td>
</tr>
<tr>
<td>296 - 315</td>
<td>Chorea (Non-Huntington's Disease)</td>
<td>Les Muses, Level 3</td>
</tr>
<tr>
<td>316 - 327</td>
<td>Myoclonus</td>
<td>Les Muses, Level 3</td>
</tr>
<tr>
<td>328 - 330</td>
<td>Neuroanatomy</td>
<td>Les Muses, Level 3</td>
</tr>
<tr>
<td>331 - 358</td>
<td>Neurupharmacology</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>359 - 385</td>
<td>Psychiatric Manifestations</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>386 - 408</td>
<td>Functional (Psychogenic) Movement Disorders</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>409 - 497</td>
<td>Genetics</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>498 - 552</td>
<td>Rare Genetic and Metabolic Diseases</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>553 - 564</td>
<td>Gene and Cell-Based Therapies</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>565 - 600</td>
<td>Restless Leg Syndrome, RBD and Other Sleep Disorders</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>601 - 639</td>
<td>Quality of Life</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>640 - 647</td>
<td>Caregiver Burden</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>648 - 685</td>
<td>Physical and Occupational Therapy</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>686 - 757</td>
<td>Other</td>
<td>Agora 2 East, Level 2</td>
</tr>
<tr>
<td>758 - 1165</td>
<td>Parkinsonisms and Parkinson-Plus</td>
<td>Agora 3, Level 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Les Muses, Level 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>1166 - 1178</td>
<td>Classification of Movement Disorders</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>1179 - 1196</td>
<td>Rating Scales</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>1197 - 1244</td>
<td>Neurophysiology</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>1245 - 1361</td>
<td>Dystonia</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>1362 - 1378</td>
<td>Spasticity</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>1379 - 1390</td>
<td>Tics/Tourette</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>1391 - 1447</td>
<td>Tremor</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>1448 - 1476</td>
<td>Drug-Induced Movement Disorders</td>
<td>Agora 2 East, Level 2</td>
</tr>
<tr>
<td>1477 - 1494</td>
<td>Education / History in Movement Disorders</td>
<td>Agora 2 East, Level 2</td>
</tr>
<tr>
<td>1495 - 1511</td>
<td>Pediatric Movement Disorders</td>
<td>Agora 2 East, Level 2</td>
</tr>
<tr>
<td>1512 - 1521</td>
<td>Environmental Causes</td>
<td>Agora 2 East, Level 2</td>
</tr>
<tr>
<td>1522 - 1650</td>
<td>Non-Motor Symptoms</td>
<td>Agora 3 West, Level 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Agora 3 East, Level 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Agora 3 North, Level 3</td>
</tr>
<tr>
<td>1651 - 1750</td>
<td>Cognition and Cognitive Disorders</td>
<td>Agora 3 East, Level 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Agora 3 North, Level 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Les Muses, Level 3</td>
</tr>
<tr>
<td>1751 - 1793</td>
<td>Physiology and Pathophysiology</td>
<td>Les Muses, Level 3</td>
</tr>
<tr>
<td>1794 - 1847</td>
<td>Epidemiology</td>
<td>Les Muses, Level 3</td>
</tr>
<tr>
<td>1848 - 2001</td>
<td>Neuroimaging</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>2002 - 2092</td>
<td>Surgical Therapy</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>2093 - 2139</td>
<td>Non-Pharmacological Interventions</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>2140 - 2198</td>
<td>Phenomenology and Clinical Assessment of Movement Disorders</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>LBA 1 - LBA 22</td>
<td>Late-Breaking Abstracts</td>
<td>Agora 2 East, Level 2</td>
</tr>
</tbody>
</table>
# Guided Poster Tour Schedule

<table>
<thead>
<tr>
<th>Date &amp; Time</th>
<th>Guided Poster Tour Session</th>
<th>Abstract Category(s)</th>
<th>Meet at Poster Number</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, September 23, 13:45 – 15:15</td>
<td>GPT 1: Rare Inherited Disorders</td>
<td>Huntington's Disease; Rare Genetic and Metabolic Diseases</td>
<td>1</td>
<td>Agora 3 West, Level 3</td>
</tr>
<tr>
<td></td>
<td>GPT 2: Treatment Supported by an unrestricted educational grant from Adamas Pharmaceuticals Inc.</td>
<td>Clinical Trials, Pharmacology and Treatment; Gene and Cell-Based Therapies</td>
<td>57</td>
<td>Agora 3 West, Level 3</td>
</tr>
<tr>
<td></td>
<td>GPT 3: Genetics</td>
<td>Genetics</td>
<td>409</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td>Tuesday, September 24, 13:45 – 15:15</td>
<td>GPT 4: Parkinsonisms and Parkinson-Plus Supported by an unrestricted educational grant from Biogen</td>
<td>Parkinsonisms and Parkinson-Plus</td>
<td>758</td>
<td>Agora 3 West, Level 3</td>
</tr>
<tr>
<td></td>
<td>GPT 5: Parkinsonisms and Parkinson-Plus Supported by an unrestricted educational grant from Adamas Pharmaceuticals Inc.</td>
<td>Parkinsonisms and Parkinson-Plus</td>
<td>962</td>
<td>Les Muses, Level 3</td>
</tr>
<tr>
<td></td>
<td>GPT 6: Neurophysiology</td>
<td>Neurophysiology</td>
<td>1197</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td></td>
<td>GPT 7: Dystonia</td>
<td>Dystonia</td>
<td>1245</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td></td>
<td>GPT 8: Hyperkinetic Disorders</td>
<td>Classification of Movement Disorders; Drug-Induced Movement Disorders; Tremor</td>
<td>1166</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td></td>
<td>GPT 10: Cognition and Cognitive Disorders</td>
<td>Cognition and Cognitive Disorders</td>
<td>1651</td>
<td>Agora 3 East, Level 3</td>
</tr>
<tr>
<td></td>
<td>GPT 11: Neuroimaging</td>
<td>Neuroimaging</td>
<td>1848</td>
<td>Les Muses Terrace, Level 3</td>
</tr>
<tr>
<td></td>
<td>GPT 12: Phenomenology and Epidemiology of Movement Disorders</td>
<td>Epidemiology; Phenomenology and Clinical Assessment of Movement Disorders</td>
<td>1794</td>
<td>Les Muses, Level 3</td>
</tr>
</tbody>
</table>
### MDS Pavilion Schedule

The MDS Pavilion is an interactive presentation space designed to provide International Congress delegates with a comfortable atmosphere while presenting valuable information regarding the Society. Learn about various MDS initiatives and programs, gain MDS expert advice, and discover ways to get involved with MDS. The MDS Pavilion will be located in Les Muses Terrace, Level 3.

#### Monday, September 23, 2019

**LIVE Demo: How to Initiate a Movement Disorders Exam**  
10:00 – 10:30  
Presenters: Kailash Bhatia, United Kingdom  
Philip Thompson, Australia  
MDS experts will provide useful tips and advice to make the most out of your patient exam time.

**Tips for a Successful Presentation and Distinguishing Yourself from the Crowd**  
12:30 – 12:45  
Presenters: Stanley Fahn, USA  
David Burn, United Kingdom  
MDS Experts will discuss the best techniques for a successful live presentation and pitfalls to avoid.

**Journal Editors Guide: How to Submit a Paper and Get it Accepted in Movement Disorders**  
15:15 – 15:30  
Presenters: José Obeso, Spain  
Kailash Bhatia, United Kingdom  
Marcelo Merello, Argentina  
A. Jon Stoessl, Canada  
MDS Journal Editors will provide step-by-step instructions and advice to get a paper published.

#### Tuesday, September 24, 2019

**Developing a Private Practice for Deep Brain Stimulation (DBS)**  
12:30 – 12:45  
Presenters: Arif Dalvi, USA  
Valerie Fraix, France  
Learn the approach to developing DBS in a private practice.

**Young Members Group**  
15:15 – 15:30  
Presenters: Thiago Cardoso Vale, Brazil  
Margherita Fabbri, Portugal  
Learn about the MDS Young Members Group and other young delegate offerings.

#### Wednesday, September 25, 2019

**How to Advance as a Young Movement Disorders Researcher**  
9:30 – 10:00  
Presenters: David Standaert, USA  
Andrew Siderowf, USA  
MDS experts will provide useful tips and advice on advancing in the field of Movement Disorders research.

**Multidisciplinary Care: Parkinson’s Disease**  
12:00 – 12:30  
Presenters: Suketu Khandhar, USA  
Bastiaan Bloem, Netherlands  
Learn the approach to identifying, evaluating and treating those living with Parkinson’s disease by incorporating primary care, general neurology, mental health, therapy services and neurosurgery (among other disciplines) for every patient.

**Getting to Know MDS Leadership**  
14:30 – 15:00  
Presenter: Claudia Trenkwalder, Germany  
Francisco Cardoso, Brazil  
MDS leadership will explain their professional journey and provide insight on their success.

---

The MDS Pavilion is sponsored by Medtronic.
International Congress Events

Sunday, September 22, 2019

Welcome Ceremony
19:30 – 21:30
Location: Apollon Auditorium, Level 2, 3

All International Congress delegates are warmly invited to attend the International Congress Welcome Ceremony. This event is open to all registered delegates. MDS does not allow exhibitors and guests to attend this event.

Tuesday, September 24, 2019

Young Delegates Networking Event
19:30 – 21:30
Location: Le Palace (about 600m away from the Nice Acropolis Convention Centre)

MDS invites all registered International Congress delegates to attend the Young Delegates Networking Event. This event is located within walking distance of the Convention Centre.

This event will provide an excellent opportunity for delegates who are in the beginning phase of their career to network and socialize with other up-and-coming experts in the field.

MDS does not allow exhibitors and guests to attend this event.

The Young Delegates Networking Event is sponsored by Acorda Therapeutics and Medtronic.

Wednesday, September 25, 2019

MDS Video Challenge
19:00 – 22:00
Location: Apollon Auditorium, Level 2, 3

Please join Masters of Ceremony, Anthony Lang and Kapil Sethi, as they host a world-renowned panel of Movement Disorders experts in guiding participants through unique Movement Disorder cases. The cases will be presented by representatives from Movement Disorder Centers around the world and discussed by the Panel of Experts. Awards will be given for the most interesting and challenging cases. Country pride will add an enjoyable spirit of competition to this event. The goal of this session is for delegates to learn from a series of unusual, highly interesting patients and see how senior experts approach these types of challenging cases.

The Panel of Experts:
Stewart Factor, USA
Manju Kurian, United Kingdom
Tiago Mestre, Canada
Francesca Morgante, United Kingdom
Martin Paucar Arce, Sweden

This event is open to all registered delegates. MDS does not allow exhibitors and guests to attend this event.

The MDS Video Challenge is sponsored by Boston Scientific.
About MDS

MDS Officers (2017-2019)

President
Christoper Goetz, USA

President-Elect
Claudia Trenkwalder, Germany

Secretary
Susan Fox, Canada

Secretary-Elect
Bastiaan Bloem, Netherlands

Treasurer
Victor Fung, Australia

Treasurer-Elect
Louis Tan, Singapore

Past-President
Oscar Gershanik, Argentina

MDS International Executive Committee
Charles Adler, USA
Daniela Berg, Germany
Shengdi Chen, People’s Republic of China
Carlos Cosentino, Peru
Joaquim Ferreira, Portugal
Jeffrey Kordower, USA
Mayela Rodriguez Violante, Mexico
D. James Surmeier, USA
Pille Tabas, Estonia
Ryosuke Takahashi, Japan

International Congress Oversight Committee
Chair: Matthew Stern, USA
Jean-Christophe Corvol, France
Gunther Deuschl, Germany
Victor Fung, Australia
Oscar Gershanik, Argentina
Christopher Goetz, USA
H.A. Jinnah, USA
Claudia Trenkwalder, Germany

Congress Local Organizing Committee
Chair: Jean-Christophe Corvol
Philippe Damier
Luc Defebvre
Franck Durif
Alexandra Durr
Caroline Giordana
Wassilios Meissner
Elena Moro
Olivier Rascol
Christine Tranchant
Marie Vidalilhet

Congress Scientific Program Committee
Chair: H.A. Jinnah, USA
Co-Chair: Jean-Christophe Corvol, France
Roongroj Bhidayasiri, Thailand
Vincenzo Bonifati, Netherlands
M. Angela Cenci Nilsson, Sweden
Shengdi Chen, People’s Republic of China
Steven Frucht, USA
Emilia Gatto, Argentina
Christopher Goetz, USA
Jennifer Goldman, USA
Etienne Hirsch, France
Roland Dominic Jamora, Philippines
Beomseok Jeon, South Korea
Han-Joon Kim, South Korea
Vladimir Kostic, Serbia
Shen-Yang Lim, Malaysia
Irene Litvan, USA
Karen Marder, USA
Wassilios Meissner, France
Vincent Mok, Hong Kong
Elena Moro, France
Alice Nieuwboer, Belgium
Maria Stamelou, Greece
Matthew Stern, USA
Antonio Strafella, Canada
Carolyn Sue, Australia
Ryosuke Takahashi, Japan
Helio Teive, Brazil
Claudia Trenkwalder, Germany

Past-Presidents
2015-2017 Oscar Gershanik, Argentina
2013-2015 Matthew Stern, USA
2011-2013 Gunther Deuschl, Germany
2009-2011 Philip Thompson, Australia
2007-2009 Anthony Lang, Canada
2005-2006 Andrew Lees, United Kingdom
2003-2004 C. Warren Olanow, USA
2001-2002 Werner Poewe, Austria
1999-2000 Mark Hallett, USA
1997-1998 Eduardo Tolosa, Spain
1995-1996 Joseph Jankovic, USA
1991-1994 C. David Marsden, United Kingdom
1988-1991 Stanley Fahn, USA

International Medical Society For Motor Disturbances Past-Presidents
1993-1994 C. Warren Olanow, USA
1991-1992 Bastian Conrad, Germany
1989-1990 Mark Hallett, USA
1987-1988 Mario Manfredi, Italy
1985-1986 C. David Marsden, United Kingdom

MDS International Secretariat
International Parkinson and Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
E-mail: info@movementdisorders.org
Faculty Listing

Tim Anderson, New Zealand 3102
Mathieu Anheim, France 3102
Angelo Antonini, Italy 1102, 4208
Selma Aybek Rusca, Switzerland 2208
Jean-Philippe Azulay, France 2102
Peter Bain, United Kingdom 3101
Fabrizio Benedetti, Italy 4203
Daniela Berg, Germany 1101
Erwan Bezard, France 5101
Kailash Bhatia, United Kingdom 3101
Roongroj Bhidayasiri, Thailand 3516
Craig Blackstone, USA 4206
Bastiaan Bloem, Netherlands 4309
Vincenzo Bonifati, Netherlands 3204, 5103
Alexis Brice, France 4207
Helen Bronte-Stewart, USA 2102
Francisco Cardoso, Brazil 4515
Miryam Carecchio, Italy 4516
Anna Castrioto, France 3516
Jesse Cedarbaum, USA 3208
M. Angela Cenci Nilsson, Sweden 4208
K. Ray Chaudhuri, United Kingdom 4309
Cynthia Comella, USA 2101
Maria Fiorella Contarino, Netherlands 2102
Mark Cookson, USA 4207
Jean-Christophe Corvol, France 3412, 4101
Esther Cubo Delgado, Spain 2616
Philippe Damier, France 4208
William Dauer, USA 3206
Ryan Davis, Australia 4207
Marina De Koning-Tijssen, Netherlands 3205
Günther Deuschl, Germany 3617
David Devos, France 2205
Nico Diederich, Luxembourg 3203
Bruno Dubois, France 2203
Franck Durif, France 1101
Alexandra Durr, France 2206
Darius Ebrahimi-Fakhari, USA 3310
Mark Edwards, United Kingdom 2208
Carsten Eggers, Germany 2309
Rodger Elble, USA 3101
Terry Ellis, USA 3411
Stewart Factor, USA MDS Video Challenge
Stanley Fahn, USA 3208
Alessandra Fanciulli, Austria 4309
Alfonso Fasano, Canada 4618
Gilles Fenelon, France 3203
Emilio Fernandez Alvarez, Spain 3310
Joaquim Ferreira, Portugal 4203
Susan Fox, Canada 1101
Jennifer Friedman, USA 2413
Steven Frucht, USA 3102, 3205
Victor Fung, Australia 4102
Nicholas Galifianakis, USA 4310
Ziv Gan-Or, Canada 4207
Christos Ganos, Germany 2207
Pedro Garcia Ruiz, Spain 4205
Emilia Gatto, Argentina 4205
Pierre Genton, France 3205
Oscar Gershman, Argentina 4208, 5102
Nir Giladi, Israel 1102
Christopher Goetz, USA 2101, 4203, 5103
Lawrence Golbe, USA 2204
Jennifer Goldman, USA 1102, 2203
Mark Hallett, USA 4206
Glenda Halliday, Australia 5101
Clement Hamani, Canada 2102
Andreas Hartmann, France 2207
Rick Helmich, Netherlands 3101
Tove Henriksen, Denmark 2411
Etienne Hirsch, France 5101, 5103
Carole Ho, USA 3208
Jerome Honnorat, France 4102
Michael Howell, USA 4617
Michele Hu, United Kingdom 4617
Sandrine Humbert, France 4204
Sarosh Irani, United Kingdom 4102
Klaus Jahn, Germany 2617
Joseph Jankovic, USA 2515
Beomske Jeon, South Korea 2208, 5102
Joohi Jimenez-Shahed, USA 4413
H.A. Jinnah, USA 2205, 3208
Ryuji Kaji, Japan 3206
Han-Joon Kim, South Korea 2310, 3415
Agnete Kirkeby, Denmark 2618
Christine Klein, Germany 2101, 4207
Thomas Klopstock, Germany 2205
## Faculty Listing

<table>
<thead>
<tr>
<th>Name</th>
<th>Country/Region</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzi Kluger, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joachim Krauss, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rejko Krueger, Luxembourg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andrea Küehn, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manju Kurian, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kathrin LaFaver, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vivek Lal, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anthony Lang, Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jee-Young Lee, South Korea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Margaret Lee, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stephane Lehericy, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simon Lewis, Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shen-Yang Lim, Malaysia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patricia Limousin, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irene Litvan, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stefan Lorenzl, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elan Louis, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wim Mandemakers, Netherlands</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karen Marder, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laura Marsh, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Davide Martino, Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Victor McConvey, Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wassilios Meissner, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niccolò Mencacci, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aurelie Meneret, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tiago Mestre, Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Janis Miyasaka, Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hidehiro Mizusawa, Japan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brit Mollenhauer, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Austen Moore, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Francesca Morgante, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elena Moro, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huw Morris, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alice Nieuwboer, Belgium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jorik Nonnekes, Netherlands</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jill Ostrem, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genko Oyama, Japan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pramod Pal, India</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stéphane Pafi, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Massimo Pandolfo, Belgium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isabel Parees, Spain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Martin Paucar Arce, Sweden</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maria Teresa Pellecchia, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Claudia Perandones, Argentina</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maria Elisa Piemonte, Brazil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sean Pittcock, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Werner Poewe, Austria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rose Pons, Greece</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ron Postuma, Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olivier Rascol, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stephen Reich, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irena Rektorova, Czech Republic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gesine Respondek, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mayela Rodriguez Violante, Mexico</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raymond Rosales, Philippines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emmanuel Roze, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Janet Rucker, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evžen Růžička, Czech Republic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ludger Schöels, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael Schwarzchild, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kapil Sethi, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aasef Shaikh, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ali Shalash, Egypt</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huifang Shang, People's Republic of China</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hiroshi Shibasaki, Japan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andrew Siderowf, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tatyana Simuni, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Friederike Sixel-Doring, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elizabeth Slow, Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maria Stamelou, Greece</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iva Stankovic, Serbia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matthew Stern, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fabrizio Stocchi, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jon Stone, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antonio Strafella, Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D. James Surmeier, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matthís Synofzik, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarah Tabrizi, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Louis Tan, Singapore</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caroline Tanner, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Helio Teive, Brazil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sue Thomas, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michele Tinazzi, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>François Tison, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Masahiko Tomiyama, Japan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Christine Tranchant, France</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Faculty Listing

Claudia Trenkwalder, Germany
2101, 5103

Enza Valente, Italy
3204

Martje Van Egmond, Netherlands
3205

Thilo Van Eimeren, Germany
2310

Charles Venuto, USA
3412

Marie Vidailhet, France
1104, 3206

Aleksandar Videnovic, USA
3309

Angela Vincent, United Kingdom
4102

Daniel Weintraub, USA
4309

Gregor Wenning, Austria
1103

Ana Westenberger, Germany
3413

Caroline Williams-Gray, United Kingdom
2203

Juliane Winkelmann, Germany
3309

Joerg Wissel, Germany
4206

Yulia Worbe, France
2207

pdmonitor

Standing by you, at every move you make!

A non-invasive continuous monitoring system, for patients with Parkinson’s disease

powered by pd neurotechnology®
medical solutions

www.pdneurotechnology.com

AD_A_V1.2_20190729
Acknowledgements

The International Congress of Parkinson's Disease and Movement Disorders wishes to acknowledge the following commercial supporters:

Platinum Plus Level

[Logos of sponsors]

Platinum Level

[Logos of sponsors]

Silver Level

[Logos of sponsors]

Bronze Level

Ipsen Innovation

The International Congress of Parkinson's Disease and Movement Disorders Scientific Program is supported through an unrestricted medical education grant from Ipsen Innovation.
SEPTEMBER 13-17
PHILADELPHIA, PA
USA
2020

SAVE THE DATE

INTERNATIONAL CONGRESS OF
PARKINSON’S DISEASE AND
MOVEMENT DISORDERS®
A bientôt à Paris

Abstract submission deadline
08 January 2020

Early registration deadline
16 March 2020

Time for Action
INBRIJA™ (levodopa inhalation powder) is indicated for intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD) treated with carbidopa/levodopa.

**PETER A. LEWITT, MD**
Wayne State University School of Medicine
Henry Ford West Bloomfield Hospital
West Bloomfield, MI, USA

**MARK LEW, MD**
Keck/USC School of Medicine
Los Angeles, CA, USA

**FERNANDO PAGAN, MD**
Georgetown University Hospital
Washington, DC, USA

Tuesday, September 24, 2019, 12:45-13:45
Les Muses 2, Level 3, Nice Acropolis Convention Centre
Lunch will be provided

Visit **Booth #78** to find out more

Inbrija is approved in the US and not approved in the EU/France

**Selected Important Safety Information**
INBRIJA is contraindicated in patients taking or who have recently taken (within 2 weeks) nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine) due to risk of hypertension. Discontinue use of nonselective MAO inhibitors at least 2 weeks prior to initiating INBRIJA.

Please see additional Important Safety Information on the adjacent pages.
At Adamas, we work every day to meaningfully enhance the daily living experience of those affected by Parkinson’s disease.
A symposium at the International Congress of Parkinson’s Disease and Movement Disorders, Nice, France

BEYOND MOTOR WEARING-OFF:
WHAT ARE WE MISSING?

Monday
23 September 2019
12:45–13:45

Les Muses 1,
Nice Acropolis Convention Centre

AGENDA

Professor Olivier Rascol
TOULOUSE, FRANCE
Chairman’s introduction

Professor Hubert Fernandez
CLEVELAND, USA
The spectrum of OFF

Professor Per Odin
LUND, SWEDEN
The time course of non-motor complications

Professor Joaquim Ferreira
LISBON, PORTUGAL
The time course of motor complications

Panel discussion

Lunch bags available for symposium attendees

This symposium is organised and fully sponsored by BIAL
ON/JUL19/G/239 Date of preparation: July 2019
Biogen invites you to join an engaging panel discussion on

PROGRESSIVE SUPRANUCLEAR PALSY (PSP).

This interactive presentation will help attendees understand the early clinical presentation of PSP, differentiate PSP from Parkinson’s disease, and understand the burden of disease.

Differentiating PSP

Monday, September 23, 2019
12:45 PM–1:45 PM (lunch provided)
Méditerranée 2, Level 1
Nice Acropolis Convention Centre
Nice, France

Chairperson
Jean-Christophe Corvol, MD, PhD
Hôpital Pitié-Salpêtrière

Speakers
Irene Litvan, MD, MSc, FAAN, FANA
University of California San Diego Health

Anette Schrag, PhD, FRCP
University College London Queen Square Institute of Neurology
INTRODUCING
THE M-STAR TRIAL
A PHASE 3 CLINICAL TRIAL FOR PEOPLE WITH MSA

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND
SAFETY OF THE MYELOPEROXIDASE INHIBITOR BHV-3241 IN
SUBJECTS WITH MULTIPLE SYSTEM ATROPHY

Enrolling patients with MSA in the US and EU (AUSTRIA, FRANCE,
GERMANY, and UK) to investigate whether a new investigational study
drug (BHV-3241) may potentially slow the progression of the disease. Key
inclusion criteria include the following:

1. Diagnosis of probable or possible MSA according to consensus clinical
criteria (Gilman et al 2008), including subjects with MSA of either subtype
(MSA-P or MSA-C).

2. Able to ambulate without the assistance of another person, defined as
the ability to take at least 10 steps. Use of assistive devices (e.g., walker or
cane) is allowed.

3. Anticipated survival of at least 3 years at the time of Screening, as
judged by the Investigator.

For more information about the study please search on
clinicaltrials.gov for NCT03952806
or visit the website at
www.MSAresearchstudy.com
A randomized, blinded sham pivotal study was performed to assess the safety and efficacy of unilateral focused ultrasound thalamotomy for patients with essential tremor. During the clinical trial, 56 subjects received focused ultrasound treatment and 19 received the sham procedure and then crossed over. Of these 75 subjects, a total of 54 are included in the 3-year analysis of the long-term study results.

**HAND TREMOR.** The tremor severity score (CRST Part A posture score) improved 76.5% over baseline at 3-year follow-up for combined (focused ultrasound and crossover) subjects.

**FUNCTIONAL DISABILITY.** Improvement in tremor/motor function (CRST Part A & B) was 53% at three years. Functional disability (CRST Part C) showed a 56.9% improvement from baseline at three years.

**SAFETY.** Long-term safety profile confirms that 74% of adverse events (AEs) were mild and the rest were moderate. Of the total AEs, 48% resolved within 30 days of the procedure. AEs that persisted at 3 years included gait disturbance (2%), imbalance (4%), musculoskeletal weakness (2%), unsteadiness (4%) and numbness (9%). The number in parenthesis is the percentage of active subjects experiencing these adverse events.

---

1For up to date clinical data, refer to the Information for Prescribers: [https://www.insightec.com/media/31393/exablateneuroinformationfor-prescribers0usa.pdf](https://www.insightec.com/media/31393/exablateneuroinformationfor-prescribers0usa.pdf)

CE Intended Use: The Exablate System 4000 Transcranial MR guided focused ultrasound is intended for thermal ablation of targets in the thalamus, sub thalamus and pallidum regions of the brain.


PUB41004338 Rev. 1
ONE THING IN MIND, PROTECTING WHAT MAKES US WHO WE ARE

TUESDAY, SEPTEMBER 24, 2019 12:45–13:45 • MEDITERRANEE 1 (MED 1) LEVEL 1

Ever wondered how digital technology changing our day-to-day life is also changing the way we assess and understand disorders such as Huntington’s disease and Parkinson’s disease?

Join us for this symposium for a unique opportunity to hear leading experts in the field discuss how remote, digital monitoring outcomes correlate with clinical data, providing a longitudinal, continuous and objective assessment of disease progression, enhancing our understanding of these disorders beyond clinic visits.

We will discuss how digital monitoring technologies are being used today in clinical trials, will show evidence of reliability and validity of the technology, and will address the opportunities and challenges of bringing these technologies into the clinical setting.

We will look for your input too! What are your thoughts and questions about remote assessments? How can this lead to better outcomes for patients?

We look forward to welcoming you to this thought-provoking symposium!

Chair
Sohini Chowdhury,
The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA

Faculty
Huntington’s disease
Dr Ralf Reilmann, George Huntington Institute, Muenster, Germany
Dr Edward Wild, University College London Huntington’s Disease Centre, London, UK

Parkinson’s disease
Professor Bastiaan R. Bloem, Radboud University Medical Center, Nijmegen, The Netherlands
Dr Tanya Simuni, Northwestern University, Feinberg School of Medicine Chicago, IL, USA

This symposium is initiated and funded by Roche. Job code NP/PIPE/1907/0007 Date of preparation: July 2019
Debating Therapeutic Advancements In Parkinson’s Disease: Are You A Realist Or An Idealist?

Sunday, September 22
13:15 – 14:15pm
Optional lunch to be provided

Nice Acropolis Convention Centre
Mediterranee 2 Room – Level 1
Nice, France

**Topic/Speakers:**

**The Realist** – We Are So Close: Continued Advances In Treating Motor Fluctuations Provide The Most Impactful Improvements In Parkinson’s Disease.
*Speaker: Alberto Espay, M.D.*

**The Idealist** – It Is Now Time To Focus Our Attention On The Greatest Unmet Needs In Parkinson's Disease: Dementia And Psychosis.
*Speaker: Daniel Weintraub, M.D.*

*Moderator: Hubert H. Fernandez, M.D.*
Notes

Debating Therapeutic Advancements In Parkinson’s Disease: Are You A Realist Or An Idealist?

Sunday, September 22
13:15 – 14:15pm
Optional lunch to be provided
Nice Acropolis Convention Centre
Mediterranee 2 Room – Level 1
Nice, France

Topic/Speakers:
The Realist – We Are So Close: Continued Advances In Treating Motor Fluctuations Provide The Most Impactful Improvements In Parkinson's Disease.
Speaker: Alberto Espay, M.D.
The Idealist – It Is Now Time To Focus Our Attention On The Greatest Unmet Needs In Parkinson’s Disease: Dementia And Psychosis.
Speaker: Daniel Weintraub, M.D.
Moderator: Hubert H. Fernandez, M.D.

FP Pharmaceutical Corp. is pleased to be a supporter of the International Congress of Parkinson’s Disease and Movement Disorders.

For Patients with Parkinson's Disease
藤本製薬グループ
エフピー

FP Pharmaceutical Corp. is pleased to be a supporter of the International Congress of Parkinson’s Disease and Movement Disorders.
NICE, FRANCE
September 22 - 26, 2019

We dedicate ourselves to distribution of Selegiline in Japan.

Fujimoto Pharmaceutical Group
FP Pharmaceutical Corp.
1-3-40 Nishiotsuka, Matsubara, Osaka, 580-0011 JAPAN
Make a Parkinson’s House Call to learn more about life with Parkinson’s disease (PD) and OFF episodes through the eyes of Maggie,* a patient with moderate-to-severe PD.

*Fictional patient for illustration only.

While you’re there, see what’s new on Sunovion’s exciting innovation platform, Little Big Things™, which celebrates the latest innovations, ideas, and events that could have a big impact on the Parkinson’s community.
GUIDE XT is DBS Visualization Software that provides the ability to see implanted leads and Stimulation Field Models (SFM) in the patient’s own segmented anatomy.

Visit us at booth #72 to learn more.
THE NEXT STEP IN YOUR SMARTER DBS JOURNEY

Enhance the DBS therapy journey for you and your patients with programming that’s more intelligent, and more streamlined. Learn more at medtronic.com/smarterjourney

Visit us at our booth and innovation suite.